Cargando…
A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research
High levels of circulating Lipoprotein (a) [Lp(a)] are an independent risk factor for CVD. One of the major limitations to investigating Lp(a) biology is the need for large volumes of plasma (4–10 mL) for its isolation. We developed an isolation technique requiring only 0.4 mL of plasma yielding an...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160242/ https://www.ncbi.nlm.nih.gov/pubmed/35650291 http://dx.doi.org/10.1038/s41598-022-13040-4 |
_version_ | 1784719229756375040 |
---|---|
author | Mueller, Paul A. Yerkes, Elisabeth Bergstrom, Paige Rosario, Sara Hay, Joshua Pamir, Nathalie |
author_facet | Mueller, Paul A. Yerkes, Elisabeth Bergstrom, Paige Rosario, Sara Hay, Joshua Pamir, Nathalie |
author_sort | Mueller, Paul A. |
collection | PubMed |
description | High levels of circulating Lipoprotein (a) [Lp(a)] are an independent risk factor for CVD. One of the major limitations to investigating Lp(a) biology is the need for large volumes of plasma (4–10 mL) for its isolation. We developed an isolation technique requiring only 0.4 mL of plasma yielding an enriched Lp(a) fraction suitable for compositional and functional studies. We collected plasma from patients (n = 9) in EDTA presenting to our Center for Preventive Cardiology for CVD risk management and with circulating Lp(a) > 66 mg/dL. 0.4 mL of plasma was added to 90 µL of potassium bromide (1.33 g/mL) and subjected to our two-step density-gradient ultracentrifugation method. The first step separates VLDL and LDL from the Lp(a) and HDL fractions and the second step further separates VLDL from LDL and Lp(a) from HDL. Lp(a) is then dialyzed for up to 24 h in potassium phosphate buffer. We performed cholesterol gel electrophoresis, immunoblotting and LC-MS/MS proteomics on isolated lipoprotein fractions to confirm fraction enrichment. Functional studies including Lp(a)-dependent induction of macrophage gene expression and cholesterol efflux inhibition were performed on isolated Lp(a) to confirm its preserved bioactivity. Lp(a) yields (264 ± 82.3 µg/mL on average) correlated with Lp(a) plasma concentrations (r(2) = 0.75; p < 0.01) and represented the relative distribution of circulating apo(a) isoforms. Proteomic analyses confirm lipoprotein fraction separation. Functional integrity was confirmed by the findings that isolated Lp(a) inhibited plasminogen-dependent cholesterol efflux in HEK293T cells expressing ABCA1 and increased expressions of Il1b, Nos2 and Ccl2. We developed a small-volume isolation technique for Lp(a) suited for a range of applications used in biomedical research. The use of this technique circumvents volume-dependent limitations and expands our ability to investigate the mysteries of this deleterious lipoprotein. |
format | Online Article Text |
id | pubmed-9160242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-91602422022-06-03 A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research Mueller, Paul A. Yerkes, Elisabeth Bergstrom, Paige Rosario, Sara Hay, Joshua Pamir, Nathalie Sci Rep Article High levels of circulating Lipoprotein (a) [Lp(a)] are an independent risk factor for CVD. One of the major limitations to investigating Lp(a) biology is the need for large volumes of plasma (4–10 mL) for its isolation. We developed an isolation technique requiring only 0.4 mL of plasma yielding an enriched Lp(a) fraction suitable for compositional and functional studies. We collected plasma from patients (n = 9) in EDTA presenting to our Center for Preventive Cardiology for CVD risk management and with circulating Lp(a) > 66 mg/dL. 0.4 mL of plasma was added to 90 µL of potassium bromide (1.33 g/mL) and subjected to our two-step density-gradient ultracentrifugation method. The first step separates VLDL and LDL from the Lp(a) and HDL fractions and the second step further separates VLDL from LDL and Lp(a) from HDL. Lp(a) is then dialyzed for up to 24 h in potassium phosphate buffer. We performed cholesterol gel electrophoresis, immunoblotting and LC-MS/MS proteomics on isolated lipoprotein fractions to confirm fraction enrichment. Functional studies including Lp(a)-dependent induction of macrophage gene expression and cholesterol efflux inhibition were performed on isolated Lp(a) to confirm its preserved bioactivity. Lp(a) yields (264 ± 82.3 µg/mL on average) correlated with Lp(a) plasma concentrations (r(2) = 0.75; p < 0.01) and represented the relative distribution of circulating apo(a) isoforms. Proteomic analyses confirm lipoprotein fraction separation. Functional integrity was confirmed by the findings that isolated Lp(a) inhibited plasminogen-dependent cholesterol efflux in HEK293T cells expressing ABCA1 and increased expressions of Il1b, Nos2 and Ccl2. We developed a small-volume isolation technique for Lp(a) suited for a range of applications used in biomedical research. The use of this technique circumvents volume-dependent limitations and expands our ability to investigate the mysteries of this deleterious lipoprotein. Nature Publishing Group UK 2022-06-01 /pmc/articles/PMC9160242/ /pubmed/35650291 http://dx.doi.org/10.1038/s41598-022-13040-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Mueller, Paul A. Yerkes, Elisabeth Bergstrom, Paige Rosario, Sara Hay, Joshua Pamir, Nathalie A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research |
title | A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research |
title_full | A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research |
title_fullStr | A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research |
title_full_unstemmed | A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research |
title_short | A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research |
title_sort | method for lipoprotein (a) isolation from a small volume of plasma with applications for clinical research |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160242/ https://www.ncbi.nlm.nih.gov/pubmed/35650291 http://dx.doi.org/10.1038/s41598-022-13040-4 |
work_keys_str_mv | AT muellerpaula amethodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT yerkeselisabeth amethodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT bergstrompaige amethodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT rosariosara amethodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT hayjoshua amethodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT pamirnathalie amethodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT muellerpaula methodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT yerkeselisabeth methodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT bergstrompaige methodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT rosariosara methodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT hayjoshua methodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch AT pamirnathalie methodforlipoproteinaisolationfromasmallvolumeofplasmawithapplicationsforclinicalresearch |